2008
DOI: 10.1517/14712598.8.2.213
|View full text |Cite
|
Sign up to set email alerts
|

Oncolytic measles virus strains in the treatment of gliomas

Abstract: Background-Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy.Objective-In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas.Methods-Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translation… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
23
0
3

Year Published

2008
2008
2016
2016

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 63 publications
(28 citation statements)
references
References 42 publications
2
23
0
3
Order By: Relevance
“…These results have led to the initiation of a phase I clinical trial in recurrent glioblastoma patients, which is currently ongoing (Allen et al, 2008a;Msaouel et al, 2009a). Although MV-CEA could allow monitoring of viral replication based on detection of the measurable marker CEA in the blood, it does not allow for localization of viral spread.…”
Section: Introductionmentioning
confidence: 99%
“…These results have led to the initiation of a phase I clinical trial in recurrent glioblastoma patients, which is currently ongoing (Allen et al, 2008a;Msaouel et al, 2009a). Although MV-CEA could allow monitoring of viral replication based on detection of the measurable marker CEA in the blood, it does not allow for localization of viral spread.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, live attenuated MV Edmonston vaccine strain derivatives have been investigated as potential oncolytic agents for various types of cancer. [5][6][7][8] Three cellular proteins have been identified as MV receptors. Signaling lymphocyte activation molecule (SLAM) is predominantly expressed on cells of the immune system.…”
mentioning
confidence: 99%
“…MĂȘme si le faible effectif de patients et/ou le . Ainsi, des modifications de la protĂ©ine H ont permis sa liaison au rĂ©cepteur PSCA (prostate stem cell antigen) exprimĂ© sur les cellules cancĂ©reuses prostatiques et pancrĂ©a-tiques [14], au prostate-specific membrane antigen (PSMA) surexprimĂ© sur les cellules prostatiques [19], Ă  l'ACE exprimĂ© sur les cellules cancĂ©reuses coliques [15], au CD20 exprimĂ© par les cellules lymphomateuses [16], Ă  une forme mutante (EGFRvIII) du rĂ©cepteur Ă  l'EGF (epidermal growth factor) ou au rĂ©cepteur de l'interleukine-13, tous deux surexprimĂ©s par les cellules de gliome [17,18]. Ces changements de la spĂ©cifi-citĂ© de reconnaissance par le virus des cellules cibles doit permettre d'augmenter la sĂ©curitĂ© du traitement.…”
Section: Justification De L'utilisation Du Virus De La Rougeole En Caunclassified
“…Cependant, un cas d'encĂ©phalite aiguĂ« Ă  inclusions a Ă©tĂ© dĂ©crit chez un enfant immunodĂ©primĂ© ayant reçu une dose vaccinale de virus modification de ce modĂšle a Ă©tĂ© crĂ©Ă©e : une sĂ©quence de type interleukine 13 a Ă©tĂ© introduite Ă  l'extrĂ©mitĂ© carboxy-terminale de la protĂ©ine H ; comme les cellules de glioblastome surexpriment le rĂ©cepteur Ă  l'interleukine 13, le virus se liera de façon prĂ©fĂ©rentielle aux cellules tumorales. Dans ce modĂšle, les animaux traitĂ©s avec ce virus modifiĂ© n'ont prĂ©sentĂ© aucun signe de toxicitĂ© [18].…”
Section: Association Virus Et Traitement Immunosuppresseurunclassified